Physicochemical Properties
| Molecular Formula | C14H10N4O |
| Molecular Weight | 250.26 |
| Exact Mass | 250.085 |
| CAS # | 878581-60-3 |
| PubChem CID | 9463163 |
| Appearance | Light brown to brown solid powder |
| LogP | 1.8 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 4 |
| Rotatable Bond Count | 2 |
| Heavy Atom Count | 19 |
| Complexity | 323 |
| Defined Atom Stereocenter Count | 0 |
| SMILES | C1(C(NC2=C3C(=CC=C2)C=CC=N3)=O)=NC=CN=C1 |
| InChi Key | CYTYVKQBOOTXRP-UHFFFAOYSA-N |
| InChi Code | InChI=1S/C14H10N4O/c19-14(12-9-15-7-8-16-12)18-11-5-1-3-10-4-2-6-17-13(10)11/h1-9H,(H,18,19) |
| Chemical Name | N-quinolin-8-ylpyrazine-2-carboxamide |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | QN523 (72 hours) exhibits cytotoxicity against 12 cell lines, with IC50 values ranging from 0.1 to 5.7 μM[1]. QN523 (0.1 and 0.5 μM; 24 and 48 h; MIA PaCa-2 cells) inhibits the cell cycle at the S phase and postpones the G2-M phase entry of pancreatic cancer cells. QN523 causes MIA PaCa-2 Cells to undergo autophagy and apoptosis[1]. |
| ln Vivo | QN523 (10 and 20 mg/kg; ip; daily, for 44 d) prevents the formation of tumors in mice bearing xenografts of pancreatic cancer[1]. |
| Cell Assay |
Cell Cycle Analysis[1] Cell Types: MIA PaCa-2 cells Tested Concentrations: 0.1 and 0.5 μM Incubation Duration: 24 and 48 hrs (hours) Experimental Results: Delayed for pancreatic cancer cells to enter the G2-M phase because of accumulation of cells in the S phase. Apoptosis Analysis[1] Cell Types: MIA PaCa-2 cells Tested Concentrations: 0.1 and 0.5 μM Incubation Duration: 24 and 48 hrs (hours) Experimental Results: Increased the number of apoptotic cells in time- and dose-dependent manner. |
| Animal Protocol |
Animal/Disease Models: NOD/SCID (severe combined immunodeficient) mouse of pancreatic cancer xenografts (6 weeks of age) Doses: 10 and 20 mg/kg Route of Administration: intraperitoneal (ip)administration; 1-9 days (10 mg/kg), 10-44 days (20 mg/kg) Experimental Results: Delayed growth of the tumors, and no systemic toxicity. |
| References |
[1]. Induction of Genes Implicated in Stress Response and Autophagy by a Novel Quinolin-8-yl-nicotinamide QN523 in Pancreatic Cancer. J Med Chem. 2022 Apr 28;65(8):6133-6156. |
Solubility Data
| Solubility (In Vitro) | DMSO : ≥ 16.67 mg/mL (66.61 mM) |
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples. Injection Formulations (e.g. IP/IV/IM/SC) Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] *Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline) Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline) Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline) Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil) Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). Oral Formulation 3: Dissolved in PEG400 Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose Oral Formulation 6: Mixing with food powders Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.9958 mL | 19.9792 mL | 39.9584 mL | |
| 5 mM | 0.7992 mL | 3.9958 mL | 7.9917 mL | |
| 10 mM | 0.3996 mL | 1.9979 mL | 3.9958 mL |